Treatment of choice in hairy cell leukemia is:
**Core Concept**
Hairy cell leukemia (HCL) is a rare, chronic cancer of the blood characterized by the accumulation of malignant B lymphocytes in the bone marrow, spleen, and liver. The disease is often asymptomatic in its early stages, but it can lead to cytopenias, splenomegaly, and other complications if left untreated.
**Why the Correct Answer is Right**
The treatment of choice for hairy cell leukemia is cladribine (2-chlorodeoxyadenosine), a nucleoside analog that selectively kills malignant B cells. Cladribine works by inhibiting DNA synthesis and inducing apoptosis in hairy cell leukemia cells, leading to a rapid reduction in tumor burden. This medication has been shown to be highly effective in achieving complete remissions and improving quality of life in patients with HCL.
**Why Each Wrong Option is Incorrect**
**Option A:** Interferon-alpha, while sometimes used in the treatment of hairy cell leukemia, is not the treatment of choice due to its lower efficacy and higher toxicity compared to cladribine.
**Option B:** Rituximab, a monoclonal antibody targeting CD20, is not typically used as a first-line treatment for hairy cell leukemia, as it is more effective against other types of lymphomas and leukemias.
**Option C:** Fludarabine, another nucleoside analog, is sometimes used in the treatment of hairy cell leukemia, but it is not as effective as cladribine and may have more side effects.
**Clinical Pearl / High-Yield Fact**
Cladribine is typically administered intravenously for 7 days, and its efficacy can be enhanced by the use of pentostatin, another nucleoside analog, in patients who have relapsed or are refractory to cladribine therapy.
**Correct Answer: C. Cladribine.**